Clinical Scorecard: Temporal Lobe Epilepsy with Late Onset: Examination of Brain Atrophy Patterns and Alzheimer’s Disease Biomarkers

At a Glance

Key Highlights

• LO-TLE patients show normal CSF AD biomarker levels (amyloid-β, total tau, phosphorylated tau) compared to patients with mild cognitive impairment due to AD.
• No significant cortico-subcortical atrophy differences were found between LO-TLE patients and healthy controls, contrasting with widespread atrophy in MCI patients.
• LO-TLE with short disease duration exhibits cortical thickness and subcortical volumes similar to healthy controls but distinct from MCI patients with or without AD pathology.

Guideline-Based Recommendations

Diagnosis

• Use long-term video-EEG monitoring to confirm temporal lobe epileptiform activity.
• Perform high-resolution 3D T1-weighted MRI to assess structural brain changes.
• Measure CSF biomarkers including amyloid-β (Aβ1–42, Aβ1–42/Aβ1–40 ratio), total tau, and phosphorylated tau (pTAU181) to evaluate AD pathology.

Management

• Consider LO-TLE as a distinct clinical entity with normal AD biomarker profiles in early disease stages.
• Monitor for cognitive decline given the potential risk of progression to dementia, although initial CSF biomarkers may be normal.

Monitoring & Follow-up

• Regular clinical and neuropsychological follow-up to detect cognitive impairment progression.
• Repeat CSF biomarker assessment if clinical suspicion of neurodegeneration arises.
• Use MRI to monitor for emerging brain atrophy over time.

Risks

• LO-TLE patients have a 7% to 38% risk of developing dementia within 4.5 years post epilepsy onset.
• Presence of pathological CSF amyloid-β at baseline increases risk of progression to Alzheimer's disease.

Patient & Prescribing Data

Patients aged 50 years and older with late-onset temporal lobe epilepsy of unknown etiology and no cognitive impairment at baseline.

Current evidence does not indicate AD biomarker abnormalities in early LO-TLE; treatment should focus on seizure control and monitoring for cognitive decline.

Clinical Best Practices

• Employ comprehensive diagnostic evaluation including EEG, MRI, and CSF biomarker analysis for accurate characterization of LO-TLE.
• Differentiate LO-TLE from MCI and AD through combined imaging and biomarker profiling to guide prognosis and management.
• Maintain vigilance for cognitive changes during follow-up given the potential neurodegenerative overlap.

References

• Tai and Galovic scientific commentary